PDCD1LG2 and glioma: Interestingly, our study’s GNG12 expression was positively correlated with immune checkpoints, including PD-1, PDL-1, and PD-L2 in gliomas; therefore, we can combine this gene with immune checkpoint inhibitors to provide a novel glioma immunotherapy.